Danaher is trading at $212.50, down 4.09%, as healthcare-sector weakness and rising Treasury yields weigh on rate-sensitive stocks.

  • The 10-year Treasury yield reached a two-decade high on October 1.
  • A same-day report described profit-taking across high-valuation life-sciences and healthcare stocks, but identified no confirmed company-specific catalyst.
  • Danaher’s CEO transition took effect October 1; available reporting does not establish it as the cause of the decline.